Expertise in
9
conditions

Dr. Manal Abdelmalek

Gastroenterology
Mayo Clinic-Rochester
5716 Cleveland St Ste 200, 
Virginia Beach, VA 
28 Years of Experience
Expertise in
9
conditions
Mayo Clinic-Rochester
5716 Cleveland St Ste 200, 
Virginia Beach, VA 

Overview

Manal Abdelmalek is a Gastroenterologist in Virginia Beach, Virginia. Dr. Abdelmalek has been practicing medicine for over 28 years is highly rated in 9 conditions, according to our data. Her top areas of expertise are Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Enlarged Liver, and Liver Transplant.

Her clinical research consists of co-authoring 156 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Gastroenterology

Licenses

Internal Medicine in NC

Hospital Affiliations

Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Mayo Clinic-Rochester
5716 Cleveland St Ste 200, Virginia Beach, VA 23462
Other Locations
Private Diagnostic Clinic PLLC
40 Duke Medicine Cir, Durham, NC 27710

Additional Areas of Focus

Dr. Abdelmalek has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Role of Lisinopril in Preventing The Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD
Role of Lisinopril in Preventing The Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Procedure, Other
Study Drug: Lisinopril
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Statins in Adult Patients With Non-Alcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Statins in Adult Patients With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drug: Atorvastatin
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Vitamin E Dosing Study (VEDS): A Dose Finding Study of Vitamin E for the Treatment of Adult NAFLD
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drug: Vitamin E
Study Phase: Phase 2
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
Enrollment Status: Completed
Publish Date: August 13, 2025
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis
Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis
Enrollment Status: Completed
Publish Date: December 20, 2022
Intervention Type: Device
Study Phase: Not Applicable
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance (MR) Biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD)
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance (MR) Biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD)
Enrollment Status: Terminated
Publish Date: August 31, 2022
Intervention Type: Other, Drug
Study Drug: Intravenous fructose challenge
Study Phase: Phase 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Enrollment Status: Completed
Publish Date: February 23, 2022
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 07, 2019
Intervention Type: Drug
Study Phase: Phase 2
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study
Enrollment Status: Terminated
Publish Date: July 11, 2017
View 14 Less Clinical Trials

156 Total Publications

Elevated Homocysteine is Associated With Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease in a Sex- and Menopause-Specific Manner.
Elevated Homocysteine is Associated With Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease in a Sex- and Menopause-Specific Manner.
Journal: Gastro hep advances
Published: August 19, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Lewis Roberts
Gastroenterology
Expertise in
12
conditions
Dr. Lewis Roberts
Gastroenterology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Lewis Roberts is a Gastroenterologist in Virginia Beach, Virginia. Dr. Roberts is highly rated in 12 conditions, according to our data. His top areas of expertise are Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Gallbladder Disease, Liver Transplant, and Endoscopy.

Expertise in
13
conditions
Dr. Gregory Gores
Gastroenterology
Expertise in
13
conditions
Dr. Gregory Gores
Gastroenterology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Gregory Gores is a Gastroenterologist in Virginia Beach, Virginia. Dr. Gores is highly rated in 13 conditions, according to our data. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Sclerosing Cholangitis, Cholangitis, Liver Transplant, and Hepatectomy.

Expertise in
24
conditions
Dr. Samuel Han
Gastroenterology
Expertise in
24
conditions
Dr. Samuel Han
Gastroenterology

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (988.8 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances

Samuel Han is a Gastroenterologist in Virginia Beach, Virginia. Dr. Han is highly rated in 24 conditions, according to our data. His top areas of expertise are Chronic Pancreatitis, Hereditary Pancreatitis, Gastrointestinal Bleeding, Endoscopy, and Lithotripsy.

Frequently Asked Questions about Dr. Manal Abdelmalek

How do I make an appointment with Dr. Manal Abdelmalek?

You can book an appointment with Dr. Manal Abdelmalek by calling their office at 507-284-2511. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Manal Abdelmalek a top-rated expert for Non-Alcoholic Fatty Liver Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Manal Abdelmalek is classified as an Elite expert for Non-Alcoholic Fatty Liver Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Manal Abdelmalek specialize in?

While Dr. Manal Abdelmalek is a Gastroenterology, they have specific expertise in Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Manal Abdelmalek participate in research or clinical trials?

Yes. Dr. Manal Abdelmalek has published 156 articles and abstracts on conditions like Non-Alcoholic Fatty Liver Disease. You can view a list of Dr. Manal Abdelmalek's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Manal Abdelmalek accept my insurance?

Dr. Manal Abdelmalek accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 507-284-2511 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abdelmalek's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile